Thyrocare Technologies Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Limited and BSE Limited. The disclosure, made on June 04, 2026, details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBCs) and its Environmental, Social, and Governance (ESG) initiatives. The report serves as a comprehensive account of the company's sustainable practices and governance framework during the fiscal year.

The report highlights that the company generated a turnover of ₹ 774.27 Crore and recorded a net worth of ₹ 560.68 Crore. Thyrocare's operations are primarily concentrated in the diagnostic and healthcare sector, which accounted for 98.66% of its total turnover. The company operates 40 plants and 1 office nationally, alongside one international subsidiary, Thyrocare Laboratories (Tanzania) Limited.

Environmental Performance

Thyrocare reported a total energy consumption of 2272.07 Giga Joules for FY26, with an energy intensity of 42.56 GJ per crore rupees of turnover. The company has implemented initiatives to reduce its carbon footprint, including the installation of solar panels at its corporate office and two laboratory facilities. Water consumption stood at 18295 kilolitres, while water discharge was recorded at 730 kilolitres.

In terms of waste management, the company generated a total of 290.80 metric tonnes of waste, comprising 46.603 metric tonnes of plastic waste and 244.198 metric tonnes of bio-medical waste. The company ensures compliance with the Bio-Medical Waste Management Rules, 2016, through authorised vendors for disposal.

Social and Governance Metrics

The company employed a total of 2,092 employees as of March 31, 2026. Women constituted 26.67% of the total workforce. Thyrocare reported zero instances of fines, penalties, or legal proceedings against the entity or its directors and Key Managerial Personnel (KMPs) during the financial year.

The Board of Directors comprises nine members, with two women directors representing 22.22% of the Board. The company has established various policies, including the Anti-Bribery and Anti-Corruption Policy and the Whistle Blower Policy, to ensure ethical conduct and transparency.

Stakeholder Grievances

During FY26, the company received 7,389 complaints from customers, of which 17 were pending resolution at the end of the year. Employee grievances numbered 1,180, with all resolved. Shareholder grievances stood at two, with zero pending. The company maintains dedicated grievance redressal mechanisms for investors, shareholders, employees, and customers through its website and internal portals.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE594H01019/c0767bad4e8346c8.pdf

Docon Technologies Private Limited has filed its annual disclosure regarding the encumbrance of shares in Thyrocare Technologies Limited for the financial year ended March 31, 2026. The filing, submitted to the National Stock Exchange of India and BSE Limited, confirms that the promoter group has not made any new encumbrances other than those already disclosed during the year.

The company stated that it has provided an encumbrance on its entire shareholding, which constitutes 60.93% of the total share capital of Thyrocare Technologies Limited. This status was duly reported to the stock exchanges and the target company. The disclosure details the history of pledges, including releases and modifications, dating back to June 2022.

Pledging History

The filing outlines a series of transactions involving the release and creation of pledges. Notably, on September 16, 2025, the company released a pledge of 3,76,56,092 shares, reducing the encumbered stake to 0%. However, subsequent transactions in September and December 2025 saw the creation of fresh pledges, bringing the total encumbered shares to 9,69,69,696.

Impact of Bonus Issue

The increase in the number of pledged shares is attributed to a bonus issue announced by the target company. On December 1, 2025, Thyrocare Technologies Limited allotted bonus shares in a 2:1 ratio. Consequently, a fresh encumbrance was created on the newly allotted shares to maintain the pledge percentage.

Encumbrance Details

The following table summarizes the key pledging events disclosed for the financial year:

The declaration was submitted on behalf of Docon Technologies Private Limited and API Holdings Limited, both classified as Promoter and Promoter Group respectively. The authorized signatory, Madhuri Sarangdhar, confirmed that the details are accurate and complete.